



Influenza Recommendations Update and Work Group Considerations

Lisa Grohskopf, MD, MPH

October 25, 2017

Acknowledgments

Influenza Division

Noreen Alabi
Lenee Blanton
Lynnette Brammer
Joe Bresee
Alicia Budd
Jessie Chung
Jill Ferdinands
Brendan Flannery
Alicia Fry
Dan Jernigan
Jackie Katz
Krista Kniss
Natalie Kramer
Desiree Mustaquim
Sonja Olsen
Leslie Sokolow
Calli Taylor
Jerry Tokars
Tim Uyeki

Immunization Safety Office

Karen Broder
Frank Destefano
Penina Haber
Tom Shimabukuro

Immunization Services Division

Carla Black
Carolyn Bridges
Sam Graitcer
Andrew Kroger
Amy Parker Fiebelkorn
Tammy Santibanez
Jeanne Santoli
Jim Singleton
Yusheng Zhai

2017-18 ACIP Influenza Recommendation Updates

- Published in MMWR August 25, 2017
- Since publication, one influenza vaccine licensure change:
 - Afluria Quadrivalent (IIV4, Seqirus), previously licensed for ages ≥ 18 years, now licensed for ages ≥ 5 years (same age indication as trivalent formulation of Afluria)

Work Group Discussion— Flumist Quadrivalent (LAIV4)

- Discussion topics included design/analysis of the non-U.S. observational studies; shedding as a correlate of protection
- No policy change proposed for this meeting
- Anticipated for discussion at February 2018 ACIP meeting
 - Results of U.S. pediatric shedding study
 - Analysis of combined LAIV effectiveness data from U.S. observational studies
 - Systematic review of post-pandemic LAIV effectiveness

Work Group Discussion— VSD Study of Spontaneous Abortion Following Influenza Vaccine

- Discussion included
 - Early median gestational age of SAB events
 - Biologic plausibility
 - Decrease in magnitude of association from 2010-11 to 2011-12
- Previous studies (including one of similar design to the currently study, conducted prior to the 2009 pandemic) have not noted an association
- No policy change proposed for this meeting
 - Current language states that “Influenza vaccine can be given at any time during pregnancy, before and during the influenza season”
 - Age-appropriate inactivated or recombinant vaccine recommended
- Results of follow-up study anticipated in 2018 or 2019

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

